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Summary In patients with advanced head and neck squamous cell carcinoma (HNSC), evidence of cell-
mediated immunity and monocyte functional abnormalities has been reported. We studied the production of
interleukin 1 beta (IL-lbeta) and interleukin 6 (IL-6) by peripheral blood monocytes from 22 patients with
HNSC (12 larynx and ten oral cavity cancers) in comparison with monocyte cytokine production of
age-matched healthy subjects. Pure monocytes were incubated with and without lipopolysaccarides (LPS)
(10 1tg ml-') for 4 h at 37C and IL-Ibeta and IL-6 concentrations were determined in supernatants by specific
ELISA. There was no significant difference in IL-1beta levels in monocyte supernatants from cancer in
comparison to control subjects; conversely, a higher IL-6 production by unstimulated and LPS-activated cells
from HNSC patients than from controls was found. No relationship was observed between cytokine produc-
tion and cancer stage. The regression analysis evidenced a significant correlation between IL-lbeta and IL-6
monocyte-release in HNSC patients and in controls, so suggesting a possible autocrine control of IL-6
production by other cytokines.
Cells of monocyte lineage and their soluble products play
vital roles in the integration of host immunity by providing
the necessary signals for B- and T-lymphocytes, and for host
non-specific immune activation (Evans et al., 1983). In fact,
the mononuclear phagocyte has been demonstrated to be
involved at the initiation of the immune response as an
antigen-presenting cell or as a source of a variety of
cytokines, such as interleukin-Ibeta (IL-lbeta) and
interleukin-6 (IL-6) (Unanue, 1984; Schindler et al., 1990).
These are pleiotropic monokines with several common and
well-distinguished biological properties. IL-lbeta is involved
in many host reactions including immunologic, inflammatory,
endocrinologic and haemopoietic ones (Dinarello, 1988). Fur-
thermore, IL-lbeta performs a synergistic role in potentiating
natural killer cell and macrophage-mediated tumour lysis
(Matsushima et al., 1987). IL-lbeta itself has also a direct
antiproliferative or cytocidal effect on several tumour cell
lines and it primarily promotes the actions of other cytokines
(Tumour Necrosis Factor-TNF and IL-6) on cancer cells
(Morinaga et al., 1989). On the other hand IL-6 has a variety
of functions including B-cell-stimulating activity (Muraguchi
et al., 1985), and promotion of plasmocytoma growth (Van
Damme et al., 1987). Some of its activities are shared with
IL-lbeta. IL-lbeta and IL-6 both act as inducers of hepatic
acute phase proteins (Gauldie et al., 1987) and as
'haematopoietin-l' (Takai et al., 1988).
Some clinical and animal studies have evidenced an altered
capacity of monocytes from cancer patients to synthesise
IL-lbeta (Ikemoto et al., 1990; Pollack et al., 1983; Herman
et al., 1984), and recently we reported an increased IL-6
serum level and monocyte production in cancer patients
(Gallo et al., 1992).
Based on these data and on the well-known impaired
cytotoxicity and cytokine-production in peripheral blood
mononuclear cells from head and neck cancer (Walter et al.,
1985; Beauchamp et al., 1988; Wanebo et al., 1988), we
investigated IL-lbeta and IL-6 spontaneous and (LPS)-
stimulated production by freshly isolated blood monocytes
from patients with advanced head and neck squamous cancer
(HNSC) in comparison to healthy subjects.
Material and methods
The study was carried out on 22 male patients aged between
49 and 67 years (mean age 58.9 years) with carcinoma of the
larynx (n = 12) and of the oral cavity (n = 10); tumour stages
were classified according to UICC (1978) (Table I). Our
study included all patients with primary head and neck
cancer; they did not receive chemotherapy before the admis-
sion to the study; no patient received anti-inflammatory
drugs during the preceding 2 weeks. 22 age-matched healthy
subjects were also studied; all subjects were free from infec-
tions and from any drug in the 2 weeks preceding blood
sampling. Blood samples were withdrawn from fasting sub-
jects between 8 and 9 am, 2-3 days before surgery.
Cellpreparation
Mononuclear cells were separated from peripheral blood,
drawn in plastic syringes and anticoagulated with citrate (1:9
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v/v). After centrifuging at 120g for 10min, at room
temperature, platelet-rich plasma was discarded, cells were
resuspended in phosphate buffered-saline (PBS) (pH 7.4) and
centrifuged at 120g for 10min and platelets were removed.
After dilution 1:2 with PBS, cells were layered into Ficoll-
Hypaque (Lymphoprep, Immuno, Austria) and centrifuged
at 400g for 20 min at 22°C (Boyum, 1976). The cells at
interface were carefully removed with sterile plastic pipettes
and washed by centrifuging at 400g for 20 min at 4°C with
PBS. Monocytes were separated from mononuclear cells by
adherence to plastic Petri dishes. Petri dishes were precoated
with gelatin (30mgmg-', type II, Sigma, St Louis Mo) by
incubating at 37°C for 2 h. After gelatin removal plates were
dried at 40°C for 2 h and incubated with fresh sterile
autologous plasma for 1 h at room temperature. The mono-
nuclear cells, resuspended in RPMI-1640, were layered on
Petri dishes and incubated for I h at 22°C. At the end of
incubation, the medium, containing mainly lymphocytes, was
removed by aspiration. Plates were washed three times with
RPMI-1640 prewarmed to 37°C. Adherent cells were detached
by incubation with 10 ml of cold PBS-EDTA (10 mM) for
20 min at 22°C. Detached cells were removed by aspiration,
centrifuged at 400g at 4°C and resuspended in RPMI-1640
medium.
The monocytes prepared by plastic adherence were greater
than 96% non-specific esterase positive. Monocytes were
more than 99% viable by trypan blue exclusion test.
Moreover, monocytes and lymphocytes were identified by
flow cytometric analysis (Orthocyte, Ortho Diagnostic
system, Milan, Italy).
Monocytes (2 x 106 cells ml-') were incubated with lipo-
polysaccharide (LPS) 10fg ml-'. (Sigma, St Louis, Mo) for
4 h at 37TC. After incubation cell suspensions were cen-
trifuged at 400g for 15 min and supernatants were collected
and stored at - 70°C until assayed.
The assay was performed within 30 days. IL-lbeta and
IL-6 concentrations were assayed by cytokine specific
immunoassay (ELISA by Quantikine R&D System, Min-
neapolis).
Statistical analysis
The tests were performed by an IBM PS2/70 computer and
PMDP statistical software. Results are given as mean ± stan-
dard error. The statistical analysis of the results was done by
the Wilcoxon rank-sum test for unpaired data and Spear-
man's rank correlation coefficient. All P values reported are
two-tailed, with values of less than 0.05 considered stati-
stically significant.
453.9 ± 105.1 vs 425.1 ± 146.8 pg 10-6 cells for IL-lbeta and
IL-6 level, respectively). A positive regression between IL-6
and IL-lbeta production by LPS stimulated monocytes was
found both in patients (r = 0.85, P<0.0001) and in controls
(r= 0.65, P=0.001) (Figure 3).
Discussion
In this study we reported that cytokine production by
monocytes is altered in patients with head and neck cancer in
comparison to healthy subjects. An increased production of
IL-6 by monocytes from cancer patients was observed in
both unstimulated and LPS stimulated cells. Conversely,
freshly isolated monocytes from both groups did not release
detectable amounts of IL-lbeta in the absence of stimulation
and the increase in the release of this monokine after
exposure to LPS was similar in cancer patients and controls.
The finding that monocytes from HNSC did not show any
substantial differences in IL-1beta production when com-
pared with IL-lbeta release from controls, is in accordance
with previous reports in patients affected by different neop-
lasms (Economou et al., 1988; Arnould et al., 1988; Erroi et
al., 1989). At variance are the results from other authors
(Ikemoto et al., 1990; Herman et al., 1984; Pollack et al.,
1983) who found an altered capacity of monocytes to syn-
thesise IL-lbeta.
The increased IL-6 release by monocytes in HNSC patients
could be related to a functional activation of monocytes in
the host or to induction of this cytokine by other cytokines,
such as IL-lbeta and TNF-alpha. In fact, IL-lbeta and TNF
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Results
Human monocytes freshly isolated from both cancer and
healthy subjects did not produce detectable amounts of IL-
lbeta after 4-h-incubation in the absence of stimuli; neither
did unstimulated blood monocytes from controls release
appreciable amounts of IL-6, whereas in five of 22 cancer
patients small amounts (87.5 ± 14.8 pg 10-6 cells) of spon-
taneously released IL-6 were detected.
Upon LPS-stimulation for 4 h, IL-lbeta and IL-6 were
produced by monocytes from both cancer patients and
healthy subjects in detectable amounts: IL-lbeta production
by LPS stimulated monocytes was found to be without any
significant difference between cancer patients and controls
(240.1 ± 37 vs 232.1 ± 49.4 pg 10-6 cells, respectively) (Figure
1). In contrast, IL-6 production by LPS stimulated mono-
cytes from HNSC patients was significantly higher (P<0.05)
than that of controls (438.2 ± 91.2 and 54.7 ± 9.9 pg 10-6
cells, respectively) and 15 of 22 patients showed IL-6 produc-
tion out of the control range (Figure 2).
IL-lbeta and IL-6 release from monocytes of cancer sub-
jects with or without LPS stimulation, did not evidence any
statistically significant difference in relation to cancer stage
(I-IIvs III-IV Stage: 274.3 ± 36.9 vs 251.7 ± 55.5; and
Figure 1 Monocyte IL-1 beta production in control subjects and
in patients with head and neck cancer upon LPS stimulation (no
statistically significant difference).
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Figure 2 Monocyte IL-6 production in control subjects and in
patients with head and neck cancer upon LPS stimulation
(P<0.05).
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Figure 3 Relationship between IL-lbeta and IL-6 monocyte production upon LPS stimulation in cancer patients and in control
subjects.
may regulate IL-6 production in monocytes and in other cells
(Tosato et al., 1990; Kohase et al., 1986). In our study
IL-lbeta has not been found higher in patients than in
controls, but we should consider that IL-6, in its turn, inhib-
its IL-lbeta production (Schindler et al., 1990). Hence, a key
role in the increased IL-6 production might be played by
TNF-alpha, which induces appearance of IL-6 in peripheral
blood when administered in vivo (Jablons et al., 1988). Inter-
estingly, we have previously observed an increased TNF-
alpha production by peripheral blood monocytes in HNSC
(Gallo et al., 1991) possibly induced by tumour cell mem-
brane costituents (Jaemcke et al., 1990). In conclusion, our
study demonstrated that the tumour bearing state may
induce an altered cytokine release from peripheral blood
monocytes characterised by an increased IL-6 production.
Since IL-6 has multiple known biological effects including
systemic control of hepatic acute phase protein synthesis,
activation of T- B- and NK-cells, and effects on the adreno-
corticoid axis (Hirano et al., 1990), the high IL-6 release by
monocytes may be one of the mechanisms underlying the
host's immune and metabolic response to malignancy in these
cancer patients.
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